WO2007075980A3 - Lansoprazole orally disintegrating tablets - Google Patents

Lansoprazole orally disintegrating tablets Download PDF

Info

Publication number
WO2007075980A3
WO2007075980A3 PCT/US2006/048961 US2006048961W WO2007075980A3 WO 2007075980 A3 WO2007075980 A3 WO 2007075980A3 US 2006048961 W US2006048961 W US 2006048961W WO 2007075980 A3 WO2007075980 A3 WO 2007075980A3
Authority
WO
WIPO (PCT)
Prior art keywords
orally disintegrating
disintegrating tablets
lansoprazole
tablets
lansoprazole orally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/048961
Other languages
French (fr)
Other versions
WO2007075980A2 (en
WO2007075980A8 (en
Inventor
David Isaac Silver
Limor Ari-Pardo
Sivan Antler
Nava Shterman
Capua Simona Di
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Original Assignee
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/314,656 external-priority patent/US20070141151A1/en
Priority claimed from PCT/US2005/046296 external-priority patent/WO2007078271A2/en
Priority claimed from EP05257891A external-priority patent/EP1813275A1/en
Priority to CA002633825A priority Critical patent/CA2633825A1/en
Application filed by Teva Pharmaceutical Industries Ltd, Teva Pharmaceuticals USA Inc filed Critical Teva Pharmaceutical Industries Ltd
Priority to JP2008547591A priority patent/JP2009524592A/en
Priority to EP06848925A priority patent/EP1962844A2/en
Publication of WO2007075980A2 publication Critical patent/WO2007075980A2/en
Publication of WO2007075980A3 publication Critical patent/WO2007075980A3/en
Priority to IL191923A priority patent/IL191923A0/en
Anticipated expiration legal-status Critical
Publication of WO2007075980A8 publication Critical patent/WO2007075980A8/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention provides orally disintegrating tablets that readily disintegrates in the mouth, releasing enteric coated drug sub-tablets.
PCT/US2006/048961 2005-12-20 2006-12-20 Lansoprazole orally disintegrating tablets Ceased WO2007075980A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP06848925A EP1962844A2 (en) 2005-12-20 2006-12-20 Lansoprazole orally disintegrating tablets
JP2008547591A JP2009524592A (en) 2005-12-20 2006-12-20 Lansoprazole Orally Disintegrating Tablet
CA002633825A CA2633825A1 (en) 2005-12-20 2006-12-20 Lansoprazole orally disintegrating tablets
IL191923A IL191923A0 (en) 2005-12-20 2008-06-03 Lansoprazole orally disintegrating tablets

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US11/314,656 US20070141151A1 (en) 2005-12-20 2005-12-20 Lansoprazole orally disintegrating tablets
EP05257891.1 2005-12-20
USPCT/US05/46296 2005-12-20
EP05257891A EP1813275A1 (en) 2005-12-20 2005-12-20 Lansoprazole orally disintegrating tablets
PCT/US2005/046296 WO2007078271A2 (en) 2005-12-20 2005-12-20 Lansoprazole orally disintegrating tablets
US11/314,656 2005-12-20

Publications (3)

Publication Number Publication Date
WO2007075980A2 WO2007075980A2 (en) 2007-07-05
WO2007075980A3 true WO2007075980A3 (en) 2008-02-21
WO2007075980A8 WO2007075980A8 (en) 2008-07-17

Family

ID=38218650

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/048961 Ceased WO2007075980A2 (en) 2005-12-20 2006-12-20 Lansoprazole orally disintegrating tablets

Country Status (5)

Country Link
EP (1) EP1962844A2 (en)
JP (1) JP2009524592A (en)
CA (1) CA2633825A1 (en)
IL (1) IL191923A0 (en)
WO (1) WO2007075980A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044929A1 (en) * 2007-10-04 2009-04-08 Laboratorios del Dr. Esteve S.A. Oral fast distintegrating tablets
WO2009113090A2 (en) * 2008-01-17 2009-09-17 Alkem Laboratories Ltd. Process for preparing an oral formulation of an acid-sensitive benzimidazole drug
TWI441658B (en) 2008-03-11 2014-06-21 Takeda Pharmaceutical Orally-disintegrating solid preparation
CN101507718B (en) * 2009-03-03 2011-05-04 张登科 Sodium rabeprazole enteric-coated orally disintegrating tablets and preparation method thereof
FR2949061B1 (en) * 2009-08-12 2013-04-19 Debregeas Et Associes Pharma FLOATING MICROGRANULES
WO2011111027A2 (en) * 2010-03-11 2011-09-15 Dexcel Pharma Technologies Ltd. Oral dispersible delayed release tablet formulation
WO2012111024A1 (en) * 2011-02-18 2012-08-23 Suven Nishtaa Pharma Pvt Ltd Pharmaceutical compositions of dexlansoprazole
JP2020055755A (en) * 2018-09-28 2020-04-09 日本ケミファ株式会社 Enteric preparation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0773025A1 (en) * 1995-02-01 1997-05-14 Esteve Quimica, S.A. New stable galenic formulations containing an acid-labile benzimidazol compound, and production process
US5753265A (en) * 1994-07-08 1998-05-19 Astra Aktiebolag Multiple unit pharmaceutical preparation
WO1999059544A2 (en) * 1998-05-18 1999-11-25 Takeda Chemical Industries, Ltd. Orally disintegrable tablets
US6248355B1 (en) * 1995-09-21 2001-06-19 Schwarz Pharma Ag Pharmaceutical composition containing an acid-labile omeprazole and process for its preparation
EP1352660A1 (en) * 1996-01-08 2003-10-15 AstraZeneca AB Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a nsaid
WO2005092297A2 (en) * 2004-03-03 2005-10-06 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical composition comprising an acid labile drug

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753265A (en) * 1994-07-08 1998-05-19 Astra Aktiebolag Multiple unit pharmaceutical preparation
EP0773025A1 (en) * 1995-02-01 1997-05-14 Esteve Quimica, S.A. New stable galenic formulations containing an acid-labile benzimidazol compound, and production process
US6248355B1 (en) * 1995-09-21 2001-06-19 Schwarz Pharma Ag Pharmaceutical composition containing an acid-labile omeprazole and process for its preparation
EP1352660A1 (en) * 1996-01-08 2003-10-15 AstraZeneca AB Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a nsaid
WO1999059544A2 (en) * 1998-05-18 1999-11-25 Takeda Chemical Industries, Ltd. Orally disintegrable tablets
WO2005092297A2 (en) * 2004-03-03 2005-10-06 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical composition comprising an acid labile drug

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Stabilized pharmaceutical composition", INTERNET CITATION, 17 September 2002 (2002-09-17), XP002374253, Retrieved from the Internet <URL:https:priorart.ip.com/download/IPCOM000009757D/IPCOM000009757D.pdf> [retrieved on 20060325] *
OKHAMAFE A O ET AL: "EFFECTS OF SOLIDS-POLYMER INTERACTIONS ON THE PROPERTIES OF SOME AQUEOUS-BASED TABLET FILM COATING FORMULATIONS. I. MOISTURE PERMEABILITY", INTERNATIONAL JOURNAL OF PHARMACEUTICS, AMSTERDAM, NL, vol. 22, no. 2/3, 1984, pages 265 - 272, XP009014826, ISSN: 0378-5173 *

Also Published As

Publication number Publication date
WO2007075980A2 (en) 2007-07-05
JP2009524592A (en) 2009-07-02
CA2633825A1 (en) 2007-07-05
IL191923A0 (en) 2009-08-03
WO2007075980A8 (en) 2008-07-17
EP1962844A2 (en) 2008-09-03

Similar Documents

Publication Publication Date Title
EG25188A (en) Device for the packaging and dispensing of solid shaped bodies, especially oral tablets or/and capsules.
CA119221S (en) Blister package
ZA200704661B (en) Solid, orally appliance pharmaceutical administration forms containing rivaroxaban having modified release
AP2172A (en) Piping.
CA111398S (en) Bottle
AP2274A (en) Alcohol resistant dosage forms.
TNSN08071A1 (en) Solid dosage forms of valsartan and amlodipine and method of making the same
IL183357A0 (en) Oral medicament for the modified release of at least one active principle, in multimicrocapsule form
TNSN08538A1 (en) Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same
BRPI0820997A2 (en) Oral disintegration tablets comprising diphenhydramine.
CA119774S (en) Blister package
GB0419849D0 (en) Pharmaceutical combination
IL191523A0 (en) Lansoprazole orally disintegrating tablets
WO2006138503A8 (en) New regimens for oral monophasic contraceptives
ZA200900673B (en) 18-methyl-19-nor-androst-4-en-17, 17-spiroether (18-methyl-19-nor-20-spirox-4-en-3-one) and pharmaceutical preparations containing the same
EP1923074A4 (en) Orally disintegratable tablet
AP2239A (en) Direct currency conversion.
IL191923A0 (en) Lansoprazole orally disintegrating tablets
WO2006046114A3 (en) Osmotic dosage forms providing ascending drug release, and processes for their preparation
WO2007007182A3 (en) Solid and liquid dosage forms of an antiepileptic agent
AP2343A (en) Rapidly disintegrating taste-masked tablet.
ES1056676Y (en) ANTI-STRESS MOUTH.
CA116344S (en) Container for chewing gum
GB2434894B8 (en) Triangular asynchronous replication.
GB0502561D0 (en) The pill popper

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2006848925

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2633825

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008547591

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 5361/DELNP/2008

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06848925

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 200680053033.6

Country of ref document: CN